SLC5A2 and type 2 diabetes mellitus: This methodology increases the accuracy of our results by reducing confounding factors and pleiotropy, thus providing a more nuanced understanding of the safety profile of SGLT2 inhibitors, particularly regarding lower limb complications in type 2 diabetes patients (Burgess et al., 2023).